Cargando…
Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress
Coronavirus disease 2019 (COVID-19) has resulted in long-term psychiatric symptoms because of the immunologic response to the virus itself as well as fundamental life changes related to the pandemic. This immune response leads to altered tryptophan (TRP)–kynurenine (KYN) pathway (TKP) metabolism, wh...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261222/ https://www.ncbi.nlm.nih.gov/pubmed/35796878 http://dx.doi.org/10.1007/s00702-022-02525-1 |
_version_ | 1784742225326899200 |
---|---|
author | Kucukkarapinar, Melike Yay-Pence, Aysegul Yildiz, Yesim Buyukkoruk, Merve Yaz-Aydin, Gizem Deveci-Bulut, Tuba S. Gulbahar, Ozlem Senol, Esin Candansayar, Selcuk |
author_facet | Kucukkarapinar, Melike Yay-Pence, Aysegul Yildiz, Yesim Buyukkoruk, Merve Yaz-Aydin, Gizem Deveci-Bulut, Tuba S. Gulbahar, Ozlem Senol, Esin Candansayar, Selcuk |
author_sort | Kucukkarapinar, Melike |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19) has resulted in long-term psychiatric symptoms because of the immunologic response to the virus itself as well as fundamental life changes related to the pandemic. This immune response leads to altered tryptophan (TRP)–kynurenine (KYN) pathway (TKP) metabolism, which plays an essential role in the pathophysiology of mental illnesses. We aimed to define TKP changes as a potential underlying mechanism of psychiatric disorders in post-COVID-19 patients. We measured plasma levels of several TKP markers, including KYN, TRP, kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), and quinolinic acid (QUIN), as well as the TRP/KYN, KYNA/3-HK, and KYNA/QUIN ratios, in 90 post-COVID-19 patients (on the first day of hospitalization) and 59 healthy controls (on the first admission to the Check-Up Center). An online questionnaire that included the Depression, Anxiety and Stress Scale-21 (DASS-21) was used 6 months after the initial assessment in both groups. A total of 32.2% of participants with COVID-19 showed depressive symptoms, 21.1% exhibited anxiety, and 33.3% had signs of stress at follow-up, while 6.6% of healthy controls exhibited depressive and anxiety symptoms and 18.6% had signs of stress. TRP and 3-HK were negative predictors of anxiety and stress, but KYN positively predicted anxiety and stress. Moreover, TRP negatively predicted depression, while KYNA/3-HK was a negative predictor of anxiety. The correlation between depression, anxiety, and stress and TKP activation in COVID-19 could provide prospective biomarkers, especially the reduction in TRP and 3HK levels and the increase in KYN. Our results suggest that the alteration of TKP is not only a potential biomarker of viral infection-related long-term psychiatric disorders but also that the therapy targets future viral infections related to depression and anxiety. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00702-022-02525-1. |
format | Online Article Text |
id | pubmed-9261222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-92612222022-07-07 Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress Kucukkarapinar, Melike Yay-Pence, Aysegul Yildiz, Yesim Buyukkoruk, Merve Yaz-Aydin, Gizem Deveci-Bulut, Tuba S. Gulbahar, Ozlem Senol, Esin Candansayar, Selcuk J Neural Transm (Vienna) Psychiatry and Preclinical Psychiatric Studies - Original Article Coronavirus disease 2019 (COVID-19) has resulted in long-term psychiatric symptoms because of the immunologic response to the virus itself as well as fundamental life changes related to the pandemic. This immune response leads to altered tryptophan (TRP)–kynurenine (KYN) pathway (TKP) metabolism, which plays an essential role in the pathophysiology of mental illnesses. We aimed to define TKP changes as a potential underlying mechanism of psychiatric disorders in post-COVID-19 patients. We measured plasma levels of several TKP markers, including KYN, TRP, kynurenic acid (KYNA), 3-hydroxykynurenine (3-HK), and quinolinic acid (QUIN), as well as the TRP/KYN, KYNA/3-HK, and KYNA/QUIN ratios, in 90 post-COVID-19 patients (on the first day of hospitalization) and 59 healthy controls (on the first admission to the Check-Up Center). An online questionnaire that included the Depression, Anxiety and Stress Scale-21 (DASS-21) was used 6 months after the initial assessment in both groups. A total of 32.2% of participants with COVID-19 showed depressive symptoms, 21.1% exhibited anxiety, and 33.3% had signs of stress at follow-up, while 6.6% of healthy controls exhibited depressive and anxiety symptoms and 18.6% had signs of stress. TRP and 3-HK were negative predictors of anxiety and stress, but KYN positively predicted anxiety and stress. Moreover, TRP negatively predicted depression, while KYNA/3-HK was a negative predictor of anxiety. The correlation between depression, anxiety, and stress and TKP activation in COVID-19 could provide prospective biomarkers, especially the reduction in TRP and 3HK levels and the increase in KYN. Our results suggest that the alteration of TKP is not only a potential biomarker of viral infection-related long-term psychiatric disorders but also that the therapy targets future viral infections related to depression and anxiety. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00702-022-02525-1. Springer Vienna 2022-07-07 2022 /pmc/articles/PMC9261222/ /pubmed/35796878 http://dx.doi.org/10.1007/s00702-022-02525-1 Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Psychiatry and Preclinical Psychiatric Studies - Original Article Kucukkarapinar, Melike Yay-Pence, Aysegul Yildiz, Yesim Buyukkoruk, Merve Yaz-Aydin, Gizem Deveci-Bulut, Tuba S. Gulbahar, Ozlem Senol, Esin Candansayar, Selcuk Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
title | Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
title_full | Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
title_fullStr | Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
title_full_unstemmed | Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
title_short | Psychological outcomes of COVID-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
title_sort | psychological outcomes of covid-19 survivors at sixth months after diagnose: the role of kynurenine pathway metabolites in depression, anxiety, and stress |
topic | Psychiatry and Preclinical Psychiatric Studies - Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261222/ https://www.ncbi.nlm.nih.gov/pubmed/35796878 http://dx.doi.org/10.1007/s00702-022-02525-1 |
work_keys_str_mv | AT kucukkarapinarmelike psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT yaypenceaysegul psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT yildizyesim psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT buyukkorukmerve psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT yazaydingizem psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT devecibuluttubas psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT gulbaharozlem psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT senolesin psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress AT candansayarselcuk psychologicaloutcomesofcovid19survivorsatsixthmonthsafterdiagnosetheroleofkynureninepathwaymetabolitesindepressionanxietyandstress |